Skip to content

Effects of Sodium Pentaborat Based Gel on Perianal Benign Diseases

Effects of Sodium Pentaborat Based Gel on Perianal Benign Diseases. Prospective Clinical Trial

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03780998
Enrollment
250
Registered
2018-12-19
Start date
2019-01-01
Completion date
2020-01-01
Last updated
2018-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anal Fissure, Hemorrhoids, Perianal Fistula

Brief summary

New produced and patented sodium pantaborat based gel will be use for treatment of benign perianal diseases (hemooroidal disease, anal fissura anda perianal fistula)

Detailed description

Prospective randomised clinical trial planned. Older than 18 years old perianal benign diseases (grade 1 and 2 hemorroidal disease, anal fissura, uncomplicated simple perianal fistula) cases without malign tumour, cronic colorectal disases, and routine used of vasoactive medication cases were entered the study. Younger than 18 years old, diagnosed any malign tumor and/or cronic colorectal disaeses, routine used of vasoact,ve mediaction cases were exclused of the study. Group-1 (n: 50): Healthy cases (control group) Group-2 (n:50): Grade 1 hemorroidal disease cases Group-3 (n:50): Grade 2 hemorroidal disease cases Group-4 (n:50): Anal fissure cases Group-5 (n:50): Uncomplicated, simple perianal fistula cases

Interventions

DRUGLife7

Life7 will used on the perianal skin with finger tips

Sponsors

Tabriz University of Medical Sciences
CollaboratorOTHER
SB Istanbul Education and Research Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Grade 1 and 2 hemorroidal disease * Cronic anal fissura * Uncomplicated simple perianal fistula

Exclusion criteria

* Any malign tumour * Cronic colorectal disases * Routine used of vasoactive medication

Design outcomes

Primary

MeasureTime frameDescription
Lowering of leakage amount of perianal fistulesix monthsThree grade: lower, same, more
Pain symtom differencessix monthsPain Scale from level 1 to level 10.
Lowering of the grade of the hemorroidal disease (hemoroidal disease is four grades; grade 1, grade 2, grade 3, and grade 4)six monthsSurgeon general physical examination
Closing of anal fissur linesix monthsSurgeon general physical examination. Fissur line is exist or not exist

Contacts

Primary Contacterhan aysan, MD Prof
erhanaysan@hotmail.com+905322034879
Backup ContactFikrettin Sahin, Prof
fikrettinsahin@gmail.com+905338146547

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026